Contingent assessment of the COVID-19 vaccine
- PMID: 32620375
- PMCID: PMC7315946
- DOI: 10.1016/j.vaccine.2020.06.068
Contingent assessment of the COVID-19 vaccine
Abstract
The COVID-19 pandemic has not only had a negative impact on people's health and life behavior, but also on economies around the world. At the same time, laboratories and institutions are working hard to obtain a COVID-19 vaccine, which we hope will be available soon. However, there has been no assessment of whether an individual and society value a vaccine monetarily, and what factors determine this value. Therefore, the objective of this research was to estimate the individual's willingness to pay (WTP) for a hypothetical COVID-19 vaccine and, at the same time, find the main factors that determine this valuation. For this, we used the contingent valuation approach, in its single and double-bounded dichotomous choice format, which was based on a hypothetical market for a vaccine. The sample used was obtained through an online survey of n = 566 individuals from Chile. The main results showed that the WTP depends on the preexistence of chronic disease (p≤0.05), knowledge of COVID-19 (p≤0.05), being sick with COVID-19 (p≤0.05), perception of government performance (p≤0.01), employment status (p≤0.01), income (p≤0.01), health care (p≤0.05), adaptation to quarantine with children at home (p≤0.01) and whether the person has recovered from COVID-19 (p≤0.10). According to our discrete choice model in double-bounded dichotomous format, it was concluded that the individuals' WTP is US$184.72 (CI: 165.52-203.92; p < 0.01). This implies a social valuation of approximately US$2232 million, corresponding to 1.09% of the GNP per capita.
Keywords: Acceptance; COVID-19; Contingent valuation; Health economics; SARS-CoV-2; Vaccine.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Comment in
-
"Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy.Vaccine. 2020 Nov 10;38(48):7585-7586. doi: 10.1016/j.vaccine.2020.10.025. Vaccine. 2020. PMID: 33121655 Free PMC article. No abstract available.
-
Acceptance of a COVID-19 vaccine: A multifactorial consideration.Vaccine. 2020 Nov 10;38(48):7587. doi: 10.1016/j.vaccine.2020.10.026. Vaccine. 2020. PMID: 33121656 Free PMC article. No abstract available.
References
-
- Le T.T. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 - PubMed
-
- Boyle K.J. A primer on nonmarket valuation. Springer; 2017. Contingent valuation in practice; pp. 83–131.
-
- Sarmento TTR et al., Consumer Willingness to pay for a hypothetical chikungunya vaccine in Brazil and the implications. Expert Review of Pharmacoeconomics & Outcomes Research 2020,(just-accepted)doi. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous